Title: Challenges to therapy for peroxisome assembly disorders
1Challenges to therapy for peroxisome assembly
disorders
- Nancy Braverman, MS, MD
- McGIll University-MCH-RI
March 9 2010 HGEN 171-575
2Properties of peroxisomes
- Spherical, single membrane bound,
- Diameter 0.2 - 1 µm, several hundred/cell
- All eukaryotes
3Peroxisomes originate from ER membranes and by
fission of existing peroxisomes
NEXT gtgt
Click to view animation gtgt
adapted from Annu Rev Genet. 200034623-652.
Sacksteder KA, Gould SJ.
4Role of peroxins in matrix protein import
Click to view animation gtgt
Gould, Raymond, Valle.In Metab Molec Basis of
Inh Dis. Ch 129 p. 3190.
5Enzymatic pathways in peroxisomes
- Fatty acid oxidation (VLCFA, PA)
- H2O2 detoxification (catalase)
- Docohexanoic acid (DHA) synthesis
- Bile acid synthesis
- Plasmalogen (ether phospholipid) synthesis
- Cholesterol synthesis
- Glyoxylate detoxification
- Lysine catabolism (pipecolic acid)
6The 3 major metabolic pathways in peroxisomes
7Properties of peroxisomal matrix proteins
- Contain Peroxisome Targeting Sequences (PTS)
- Imported as oligomers/fully assembled proteins
- Can have dual localizations in mitochondria,
cytosol
PTS1
PTS2
-SKL
R/KLX5Q/HL
-SKL
N - terminal (-R/KLX5 Q/HL-) Presequence
cleaved internally 3 enzymes only Thiolase,
PhyH, AGPS Receptor is PEX7
C - terminal (-SKL) Most matrix
proteins Receptor is PEX5
8Genetic disorders of peroxisomes
- Multiple enzyme deficiencies Peroxisomal
Biogenesis Disorders (PBD) - Zellweger spectrum disorder (ZSD) (1/60,000)
- Rhizomelic chondrodysplasia punctata spectrum
(RCDP)(1/100,000) - Single enzyme deficiencies
- X-linked adrenoleukodystrophy (X-ALD) (1/20,000)
- 3-methyl-CoA racemase deficiency
- Adult Refsum disease
- Hyperoxaluria Type I
9Some single enzyme deficiencies can mimic PBDs
- VLCFA oxidation ? Zellweger spectrum disorder
- Acyl-CoA oxidase
- D-Bifunctional protein (hydratase/dehydrogenase)
- Plasmalogen biosynthesis ? RCDP spectrum
- DHAPAT (RCDP2)
- ADHAPS (RCDP3)
- Some PBDs mimic SEDs ?
- Adult Refsum disease causes PEX7 deficiency
10Develop therapies targeted to the metabolic
defects
-
- Phytanic acid restriction
- Reduction in VLCFA
- dietary reduction
- enhance VLCFA omega oxidation
- reduce VLCFA synthesis
- Supplementation with DHA, bile acids,
plasmalogens
11Develop therapies targeted to the molecular
defects
- Enhance activity of a defective PEX protein-
- improve protein folding
- Bypass the need for a specific PEX protein-
- upregulate a partner PEX protein
- Induce peroxisome proliferation
- Enzyme/PEX protein replacement therapy ?
- Liver/stem cell transplant ?
- Gene therapy ?
- Manipulate the intestinal microbiome?
12PBD phenotypes correlate with biochemical severity
13Phenotype correlates with severity of protein
import defect, peroxisome number and size
PX and size
Matrix protein import
Control
ZS
IRD
14Mild PBD, PEX1-G843D/G843D
PMP70
CATALASE
PTS1/PTS2
37
30
15PEX1-G843D/ G843D, expressing GFP-PTS1 reporter
No Treatment 30 oC
No Treatment 37 oC
Glycerol 5 37 oC
TMAO 200 uM 37 oC
16(No Transcript)
17Disorder-to-order conformational transitions in
protein structure and its relationship to disease
18- Lower temperature
- Chaperone (protein or drug)
- Nonspecific chemical chaperone
- Pharmacologic chaperone
- Enzyme substrate
- Protein ligand (protein kinase and kinase
inhibitor) - Vitamin cofactor
19(No Transcript)
20Conformational changes of p97 AAA ATPase during
its ATPase cycle
Bind and hydrolyze ATP generating chemical energy
that is converted into motion of the molecule.
Motion used to pull PEX5 out of the membrane
for another round of import
21Role of peroxins in matrix protein import
Click to view animation gtgt
Gould, Raymond, Valle.In Metab Molec Basis of
Inh Dis. Ch 129 p. 3190.
22High throughput chemical screen
- Cells incubated in chemicals 2 days (2000
compounds) - Negative control media alone
- Positive control TMAO and glycerol
233 chemicals rescued import
- Data indicated that they can non-competitively
bind to the ATP binding sites of proteins - Potential pharmacologic chaperones!
24Pipeline for new drugs 5-10 yrs
- Develop HT assays to screen chemical libraries
for compounds that recover target function - Best to start with in vivo assay, several
complementary assays - Confirm hits from the screening assay
- Study structure-function relationships to develop
best lead compounds - Evaluate mechanisms of recovery
- Asses pharmacokinetics half-life, metabolism,
excretion, recovery in the brain, toxicity,
tissue pathology (rodents) - Assay efficacy animal models
- Approval of drug for clinical trials or off-use
label - Ensure drug supply, design and approval of
clinical trial - Funding for clinical trial
25Intracellular distribution of AGT, a protein with
an N-terminal MTS C-terminal PTS1
26Primary hyperoxaluria type 1
- 15-20 European and North American population has
Pro11Leu missense substitution - Decreased AGT stability
- Decreased enzymatic activity
- Enhances effect of additional mutations that are
predicted to be innocuous in its absence - Redirects AGT to mitochondria
- Gly170Arg folding delay promotes mitochondrial
import
27Protein evolution depends on diet
28Cell penetrating peptides protein transduction
therapy
Endosomal exit to cytosol?
29(No Transcript)
30Role of peroxins in matrix protein import
Click to view animation gtgt
Gould, Raymond, Valle.In Metab Molec Basis of
Inh Dis. Ch 129 p. 3190.
31Understanding the pathophysiology may reveal
other targets for therapy
- Selective inactivation of PEX5 gene in neural
cells Pex5-loxP x Nestin-cre (neurons,
oligodendrocytes and astrocytes) - Pex5-loxP x CNPase-cre (oligodendrocyte)
- Abnormal compaction of myelin
- Axonal damage and transport defects
- Reactive astrocytosis and microgliosis
- CD8 T helper cells and increased cytokines
32(No Transcript)
33(No Transcript)
34(No Transcript)